Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HDM1005 phase 2 (T2D)

HDM1005 phase 2 (T2D)

HDM1005 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HDM1005
Population
t2d
Phase
2
Participants
220
Duration
20 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
HDM1005 3.0 mgt2d china20220−5.9 % vs −0.2 %
Δ −5.7 pp
—−2.6 vs −0.6——————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (2)
  • HDM1005 3.0 mg · weight_eff · Abstract, Results
    Dose-dependent body weight reductions were observed (LSM percentage change: -2.53%, -5.10%, -5.45%, -5.89% vs - 0.17% for placebo)
  • HDM1005 3.0 mg · hba1c · Abstract, Results
    the least squares mean (LSM) changes in HbA1c were -1.95%, -2.40%, -2.45%, and -2.57% for HDM1005 0.5, 1.0, 2.0, and 3.0 mg groups

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HDM1005 phase 2 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1005-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.